Spectral Medical Inc T.EDT

A must watch PMX presentation by Dr. Kellum

[hmmmmmmmm]

I can't understand why Spectral hasn't shared/ promoted this presentation by Dr Kellum. Especially as he is their CMO and they were sponsors of this symposium...

Lucky for us the other sponsor ESTOR had a link on their site.

A good way to end a good day.

https://www.youtube.com/watch?v=r7bFOVB0osw

[Gorf79]

It's a done deal and you can hear it on his voice. As expected...

[mercedesman]

Interesting video and Q&A that touched on some hot topics previously mentioned here, such as : 1. the interesting data subset of patients under  Euphrates that experienced the highest benefit from PMX - namely those with no culturable bacteria but still endotoxemic. This subgroup would otherwise have no treatment. It seems that this will be studied over time ( shout out to STT for

[Gorf79]

MM, Given your post below MM, and the apparent intent to expand PMX use beyond the "subgroup" defined in the post hoc Euphrates analysis, would you be willing to upgrade your NPV figures? I would assume that BTD status would lead you to further de risk  your calculations would it not? I would but I'm already at the top end of anybody else's range at  $50 + per share.

[Gorf79]

Also MM, and I guess AP too, What industry multiple are you using in your valuation calculations? Pharma and Biotech seem to have different multiples, at any given time. For my $52 NPV figure I am using 17 times earnings as that is a blended biotech/pharma multiple average over the previous 3 years and it is very conservative in my opinion , particularly given the anticipated market dominance I

[mercedesman]

Re upward valuation The problem is there is currently no statistical basis for quantifying the revenue potential for these groups mentioned in Italy ( and here many times)  Endotoxemuc, non culturable bacteria Covid patients suffering from gut dysbiosis and endotoxemia  >.9 EAA patients that are effectively " under dosed" within current restrictive RCT

[Gorf79]

Understood MM, And as I have previously stated, I have not included any of the substantial supply and maintenance items which will drive secondary revenue streams for both divisions. It is massive but as yet un-quantifiable! The printer and toner model is an industry I am intimately familiar with from a past life. The supplies invariably drive a better revenue stream than the hardware itself

[Gorf79]

I have also intentionally neglected to include EAA diagnostic revenues in the PMX revenue calculations. Again massive but un quantifiable. But MASSIVE!....and they own 100% of EAA's global rights. It will take newbies a bit of work to understand  precisely what they are looking at but MASSIVE is the word that always comes to mind as I study Spectral's revenue opportunity. 

[mercedesman]

I suspect that of the tiny fraction of people that know about  Spectral, most of them think that the EAA is only to be used in conjunction with PMX as a companion diagnostic. What they don't appreciate is that (IMO) the EAA should be used in ICU's world-wide as a triage tool to look for elevated levels of endotoxins when a patient presents with a multiple of symptoms.  It could

[Gorf79]

MM, It is not a stretch at all to suggest that the PMX/EAA revenue potential is 2-3 times what the company has so conservatively estimated in public disclosures. Again it is impossible to quantify the revenue opportunity, but for certain in the hands of someone like Baxter,  but it is enormous!!!  

[Accountprince]

The share value is way higher than the price it's been held at for over 2 years now.  With risk for both DIMI and PMX I felt the range was $8 to $10 a share at a 50% risk discount.  But as MM recently pointed out to me the risk has dramatically fallen so perhaps $15 to $20 a share is now closer to value. But as we can see in the market right now there's special interests that

[RickyBobbyTO]

any amount of shares purchased today will probably be shorted by hedge funds who will cover with financing paper. You literally need 20 million dollars plus worth of purchasing for the price to really move. And even then it's unlikely the company wouldn't just take 20 m financing to pay salaries. What a bunch of amateurs.   

[Accountprince]

Curious as to how you know this RickyBobby.  Shorting the share price by hedge fund(s) is presumably actions taken by people outside the "insider" crowd - third parties. Covering with financing paper implies that "insiders" are involved.  Because it's only "insiders" that have the capability to issue financing paper. If taken together should I conclude

[RickyBobbyTO]

are you new to the stock market???? How do you not know this is the question ???? How are you investing money and completely oblivious to this. For you, this is a casino. Stay out.  

[RickyBobbyTO]

no, people with a brain read financial statements. When they see the well is running dry they start shorting to cover with financing paper and clip a free warrant, relatively risk freez It's how a hedge fund operates. This isn't brain surgery, although for you I suspect it might be. 

[RickyBobbyTO]

even if not a single hedge fund was paying attention over here, last July, family offices and institutional bought 10M of paper. That overhang might still exist, those people knowing the company needs money again by reading the statements could be selling to get into this years placement and clipping the warrants again.  If you don't know the basics, why are you putting real money into

[Accountprince]

Hey RBTO.  Three successive long posts and you still don't answer the question.  What do you know? I suspect it's nada or what your handlers told you.  Gorf 79 absolutely correct about you.

[RickyBobbyTO]

 I know the company has a nearly 3 million a quarter burn rate and roughly 4 million in the bank. Unless money floats in in some unconventional way... or there is some kind of insane news like they hit 60% enrolment. There is a financing coming. @